Seeking Alpha

Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory...

Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the primary endpoint of Forced Expiratory Volume.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs